Cellebrite DI (NASDAQ:CLBT) Trading Up 7.1% – Here’s What Happened

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) rose 7.1% on Thursday . The company traded as high as $15.15 and last traded at $15.1670. Approximately 1,096,592 shares traded hands during trading, a decline of 42% from the average daily volume of 1,895,732 shares. The stock had previously closed at $14.16.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Lake Street Capital raised their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Bank of America upped their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Up 7.6%

The stock has a 50-day simple moving average of $15.74 and a two-hundred day simple moving average of $16.96. The firm has a market cap of $3.65 billion, a PE ratio of 49.15, a P/E/G ratio of 2.11 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The company had revenue of $128.82 million during the quarter, compared to the consensus estimate of $126.07 million. During the same quarter in the previous year, the company posted $0.10 EPS. Cellebrite DI’s quarterly revenue was up 28.8% compared to the same quarter last year. Research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently added to or reduced their stakes in the company. Y.D. More Investments Ltd boosted its position in shares of Cellebrite DI by 76.2% during the second quarter. Y.D. More Investments Ltd now owns 441,579 shares of the company’s stock valued at $7,065,000 after buying an additional 191,020 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Cellebrite DI by 40.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 359,764 shares of the company’s stock worth $6,652,000 after buying an additional 103,568 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Cellebrite DI during the second quarter valued at approximately $657,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Cellebrite DI during the third quarter valued at approximately $19,457,000. Finally, Moody National Bank Trust Division bought a new position in Cellebrite DI in the third quarter worth approximately $2,670,000. Institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.